Kurarinone Synergizes TRAIL-Induced Apoptosis in Gastric Cancer Cells

被引:0
作者
Wenchao Zhou
Aili Cao
Li Wang
Dazheng Wu
机构
[1] Shanghai University of Traditional Chinese Medicine,Putuo Hospital
[2] Shanghai University of Traditional Chinese Medicine,undefined
来源
Cell Biochemistry and Biophysics | 2015年 / 72卷
关键词
TRAIL; Kurarinone; Gastric cancer; Apoptosis; STAT3;
D O I
暂无
中图分类号
学科分类号
摘要
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been identified as a promising anti-tumor agent against in a variety of cancers. However, gastric cancer cells are less sensitive than other cancer cells to TRAIL-induced apoptosis. Here, we combined TRAIL with kurarinone, a natural compound, to induce apoptosis in gastric cancer cell lines SGC7901. After the cells were treated with TRAIL and/or kurarinone, the cell viability and apoptosis were examined by MTT and flow cytometry, respectively. The expression of apoptosis-associated proteins was determined by western blot and q-RT-PCR. Kurarinone at low concentration significantly potentiated the cytotoxic effect of TRAIL by enhancing apoptosis as well as cell cycle arrest at G2/Mphase. The enhancement of apoptosis TRAIL induced by kurarinone involved downregulation of anti-apoptotic proteins Mcl-1 and c-FLIP as well as inhibition of STAT3 signaling. Moreover, we found that STAT3 inhibitor could synergistically enhanced TRAIL-induced apoptosis, similar to kurarinone. Kurarinone synergizes TRAIL-induced apoptosis in human gastric cancer cells. The synergistic effect between these two drugs is associated with downregulation of Mcl-1 and c-FLIP via inhibiting STAT3 signaling. The combination of TRAIL and kurarinone might be an effective regimen for the treatment of advanced gastric cancer.
引用
收藏
页码:241 / 249
页数:8
相关论文
共 323 条
  • [1] Shin A(2011)Gastric cancer epidemiology in Korea Journal of Gastric Cancer 11 135-140
  • [2] Kim J(2010)Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells Digestive Diseases and Sciences 55 3361-3368
  • [3] Park S(2012)Targeted therapy for gastric cancer Current Treatment Options in Oncology 13 377-389
  • [4] Liu J(2013)Molecular targeted therapies in advanced gastric cancer: Does tumor histology matter? Therapeutic Advances in Gastroenterology 6 15-31
  • [5] Qu XJ(2013)Molecular profiling of gastric cancer: Toward personalized cancer medicine Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 31 838-839
  • [6] Xu L(2010)Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer British Journal of Cancer 102 506-512
  • [7] Zang Y(2008)Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer Lung Cancer 61 82-90
  • [8] Qu JL(2010)A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin’s lymphoma British Journal of Cancer 103 1783-1787
  • [9] Hou KZ(2010)Reovirus infection induces apoptosis of TRAIL-resistant gastric cancer cells by down-regulation of Akt activation International Journal of Oncology 36 1023-1030
  • [10] Liu YP(2003)Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers Cancer Science 94 1066-1073